Evaluating CT-Based Models to Predict Residual Disease and Surgical Extent in Interval Debulking Surgery for Ovarian Cancer
Posted innews OB/GYN & Women’s Health Oncology

Evaluating CT-Based Models to Predict Residual Disease and Surgical Extent in Interval Debulking Surgery for Ovarian Cancer

This study assesses the predictive accuracy of the MSKCC CT-based model for residual disease after neoadjuvant chemotherapy in advanced ovarian cancer, showing limited discrimination that improves with optimized clinical parameters. CT findings guide surgical planning but cannot exclude complex procedures.
Real-world Evidence: Managing Platelet Counts in Ovarian Cancer Patients on First-Line Maintenance Niraparib
Posted innews OB/GYN & Women’s Health Oncology

Real-world Evidence: Managing Platelet Counts in Ovarian Cancer Patients on First-Line Maintenance Niraparib

A US cohort study of 543 ovarian cancer patients revealed 37% experienced decreased platelets during niraparib maintenance. Onset typically occurred within 1 month but resolved rapidly with dose adjustments, resulting in low discontinuation rates (16%). However, discontinuations often lacked prior dose modification, indicating management optimization opportunities.